BVAS version 3 and BVAS/GPA: standing on the same line?
Introduction/objectives Birmingham vasculitis activity score (BVAS) version 3 (BVAS 3.0) and BVAS/granulomatosis with polyangiitis (BVAS/GPA) are used as indicators of disease activity in anti-neutrophil cytoplasmic antibody-associated vasculitis. We evaluated the association between these indices and the significance in patients with GPA and microscopic polyangiitis (GPA/MPA). Methods We retrospectively reviewed the records of 203 patients with GPA/MPA in our hospital. The correlation between BVAS 3.0 and BVAS/GPA with the five-factor score (FFS) and laboratory data was investigated. The episodes of all-cause mortality, end-stage renal disease, and disease relapse were counted as adverse clinical outcomes. Multivariate Cox hazard analyses were performed to assess the relationships between both indices and patient outcomes. Results Sixty-five (32.0%) and 138 (68.0%) patients with GPA and MPA were included. The median BVAS 3.0 was significantly higher in patients with MPA than in those with GPA (13.0 vs. 11.0, p = 0.015), whereas BVAS/GPA was higher in patients with GPA (4.0 vs. 3.0, p = 0.001). BVAS 3.0 and BVAS/GPA correlated significantly (r = 0.670, p < 0.001); both BVAS 3.0 and BVAS/GPA were shown to be associated with the outcomes investigated in separate Cox models. However, the correlation between BVAS 3.0 and BVAS/GPA was especially higher in a subgroup of patients with MPA than in those with GPA (MPA: r = 0.817, p < 0.001 vs. GPA: r = 0.570, p < 0.001) and with renal involvement (r = 0.676, p < 0.001). Conclusions Although both BVAS 3.0 and BVAS/GPA significantly correlated and predicted outcomes well in those with GPA/MPA, a discord was observed based on disease subtypes and organ involvement.Key Points• BVAS 3.0 and BVAS/GPA significantly correlated and predicted outcomes in those with GPA/MPA.• A discordance was also observed based on disease subtypes and organ involvement..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Clinical rheumatology - 41(2022), 11 vom: 09. Juli, Seite 3429-3437 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ahn, Sung Soo [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Anti-neutrophil cytoplasmic antibody |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR) 2022 |
|---|
| doi: |
10.1007/s10067-022-06267-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2079732315 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2079732315 | ||
| 003 | DE-627 | ||
| 005 | 20230513020124.0 | ||
| 007 | tu | ||
| 008 | 221221s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10067-022-06267-z |2 doi | |
| 035 | |a (DE-627)OLC2079732315 | ||
| 035 | |a (DE-He213)s10067-022-06267-z-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Ahn, Sung Soo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a BVAS version 3 and BVAS/GPA: standing on the same line? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR) 2022 | ||
| 520 | |a Introduction/objectives Birmingham vasculitis activity score (BVAS) version 3 (BVAS 3.0) and BVAS/granulomatosis with polyangiitis (BVAS/GPA) are used as indicators of disease activity in anti-neutrophil cytoplasmic antibody-associated vasculitis. We evaluated the association between these indices and the significance in patients with GPA and microscopic polyangiitis (GPA/MPA). Methods We retrospectively reviewed the records of 203 patients with GPA/MPA in our hospital. The correlation between BVAS 3.0 and BVAS/GPA with the five-factor score (FFS) and laboratory data was investigated. The episodes of all-cause mortality, end-stage renal disease, and disease relapse were counted as adverse clinical outcomes. Multivariate Cox hazard analyses were performed to assess the relationships between both indices and patient outcomes. Results Sixty-five (32.0%) and 138 (68.0%) patients with GPA and MPA were included. The median BVAS 3.0 was significantly higher in patients with MPA than in those with GPA (13.0 vs. 11.0, p = 0.015), whereas BVAS/GPA was higher in patients with GPA (4.0 vs. 3.0, p = 0.001). BVAS 3.0 and BVAS/GPA correlated significantly (r = 0.670, p < 0.001); both BVAS 3.0 and BVAS/GPA were shown to be associated with the outcomes investigated in separate Cox models. However, the correlation between BVAS 3.0 and BVAS/GPA was especially higher in a subgroup of patients with MPA than in those with GPA (MPA: r = 0.817, p < 0.001 vs. GPA: r = 0.570, p < 0.001) and with renal involvement (r = 0.676, p < 0.001). Conclusions Although both BVAS 3.0 and BVAS/GPA significantly correlated and predicted outcomes well in those with GPA/MPA, a discord was observed based on disease subtypes and organ involvement.Key Points• BVAS 3.0 and BVAS/GPA significantly correlated and predicted outcomes in those with GPA/MPA.• A discordance was also observed based on disease subtypes and organ involvement. | ||
| 650 | 4 | |a Anti-neutrophil cytoplasmic antibody | |
| 650 | 4 | |a Birmingham vasculitis activity score | |
| 650 | 4 | |a Granulomatosis with polyangiitis | |
| 650 | 4 | |a Microscopic polyangiitis | |
| 650 | 4 | |a Vasculitis | |
| 700 | 1 | |a Ha, Jang Woo |4 aut | |
| 700 | 1 | |a Park, Yong-Beom |4 aut | |
| 700 | 1 | |a Lee, Sang-Won |0 (orcid)0000-0002-8038-3341 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical rheumatology |d Springer International Publishing, 1982 |g 41(2022), 11 vom: 09. Juli, Seite 3429-3437 |w (DE-627)167914960 |w (DE-600)604755-5 |w (DE-576)024860131 |x 0770-3198 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2022 |g number:11 |g day:09 |g month:07 |g pages:3429-3437 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s10067-022-06267-z |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_4277 | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2022 |e 11 |b 09 |c 07 |h 3429-3437 | ||